KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Dec 2024 value amounting to $166.4 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) rose 2.69% to $170.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.7 million, marking a year-over-year increase of 2.69%. This contributed to the annual value of $166.4 million for FY2024, which is 1.55% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) is $166.4 million, which was up 1.55% from $163.8 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $166.4 million for FY2024, and its period low was $157,331 during FY2020.
  • In the last 3 years, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $163.8 million in 2023 and averaged $164.0 million.
  • Data for Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 100,641.47% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $157,331 in 2020, then rose by 2.01% to $160,493 in 2021, then skyrocketed by 100,641.47% to $161.7 million in 2022, then climbed by 1.32% to $163.8 million in 2023, then increased by 1.55% to $166.4 million in 2024.